[Drug perspectives in the treatment of invasive aspergillosis].
The frequency of infections caused by Aspergillus sp. is on the rise, and the mortality is high in the disseminated forms of the disease. Amphotericin B is theoretically the gold standard treatment, but remains inefficient in severely immunocompromised patients, particularly bone-marrow transplants. The interest of lipidic formulations of amphotericin B, triazoles, new antifungal drugs targeted on the fungal cell wall and immunomodulators is discussed.
Yeni
P
P
Service de Médecine Interne, Hôpital Bichat, Paris, France.
D000666:Amphotericin B / Q000627:therapeutic use*; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D001228:Aspergillosis / Q000628:therapy*; D016207:Cytokines / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D007371:Interferon-gamma / Q000627:therapeutic use; D017964:Itraconazole / Q000627:therapeutic use*; D008172:Lung Diseases, Fungal / Q000628:therapy*
D000903:Antibiotics, Antineoplastic; D016207:Cytokines; D017964:Itraconazole; D000666:Amphotericin B; D007371:Interferon-gamma
Perspectives médicamenteuses dans le traitement de l'aspergillose invasive.